Kim, Hyung-Ho

Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial

Noh, S. H., Park, S. R., Yang, H.-K., Chung, H. C., Chung, I.-J., Kim, S.-W., Kim, H.-H., Choi, J.-H., Kim, H.-K., Yu, W., et al. (2014) · The Lancet Oncology

Gastric Cancer Management and OutcomesIntraperitoneal and Appendiceal Malignancies

Cited by 1,049

Morbidity and Mortality of Laparoscopic Gastrectomy Versus Open Gastrectomy for Gastric Cancer: An Interim Report—A Phase III Multicenter, Prospective, Randomized Trial (KLASS Trial)

Kim, H.-H., Hyung, W. J., Cho, G. S., Kim, M. C., Han, S.-U., Kim, W., Ryu, S.-W., Lee, H.-J., & Song, K. Y. (2010) · Annals of Surgery

Gastric Cancer Management and OutcomesEsophageal Cancer Research and Treatment

Cited by 758

Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis

Cheong, J.-H., Yang, H.-K., Kim, H., Kim, W. H., Kim, Y.-W., Kook, M.-C., Park, Y.-K., Kim, H.-H., Lee, H. S., Lee, K. H., et al. (2018) · The Lancet Oncology

Gastric Cancer Management and OutcomesBreast Cancer Treatment Studies

Cited by 219